Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

Second Nature will maintain existing September prices across all doses of Mounjaro for its members, absorbing the cost ...

The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Novo Nordisk A/S (NYSE:NVO) develops, manufactures, and distributes pharmaceutical products focused on diabetes, obesity, ...

Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of ...